American Journal of Hematology

Article	Citations
	577
Therapeutic Errors Associated With Antithrombotic Medications Reported to United States Poison Centers	319
Clonal Hematopoiesis and Thrombosis	312
The latest insights into rare blood disorders: Diagnosis and treatment strategies	209
Tocilizumab for severe acute chest syndrome in a child with sickle cell disease and dramatically high interleukin‐6 values in endotracheal and pleural fluids	185
Cytopenias revealing a case of carcinocythemia with bone marrow metastasis	179
The evolving landscape of COVID‐19 and post‐COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative	134
Oh node: Extranodal nodular involvement of chronic lymphocytic leukemia in the colon	125
The impact of sex on platelet responses to aspirin in patients with peripheral artery disease	123
Identifying signs and symptoms of AL amyloidosis in electronic health records using natural language processing, diagnosis codes, and manually abstracted registry data	103
Not All Tryptase Elevations Are due to Acquired Clonal Mast Cell Disorders: When Tryptase Gene Copy Number Analysis Becomes Critical	89
Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations	81
Novel Flow Cytometric Antibody Panel and Dedicated Analysis Algorithm for Automated Fully Standardized Minimal Residual Disease Detection in Chronic Lymphocytic Leukemia	80
Teclistamab in patients with multiple myeloma and impaired renal function	79
Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia	78
The insertion site is the main risk factor for central venous catheter‐related complications in patients with hematologic malignancies	76
The Composite Immune Risk Score predicts overall survival after allogeneic hematopoietic stem cell transplantation: A retrospective analysis of 1838 cases	75
Dendritic cell vaccines extend CAR T‐cell persistence and improve the efficacy of CD19 CAR T‐cell therapy in refractory or relapsed adult B‐ALL patients	75
Characteristics and prevalence of antibiotic allergies in patients with sickle cell disease: A single‐center retrospective study	73
Secondary acquisition of the Philadelphia chromosome in acute lymphoblastic leukemia	73
Acute thrombocytopenia suggesting thrombotic microangiopathy	73
The prognostic significance of macrocytosis in patients with myelodysplastic neoplasms	73
Natural killer cells: Innate immune system as a part of adaptive immunotherapy in hematological malignancies	70
A t(6;14;9)(p22;q22;q34) three‐way translocation: Description of a cytogenetically visible variant t(6;9) in acute myeloid leukemia	69
Introduction to American Journal of Hematology Supplement: Improving Initial Care for Acute GVHD Patients	66

Pediatric refractory chronic immune thrombocytopenia: Identification, patients' characteristics, and outcome	63
TEG and ROTEM: Technology and Clinical Applications, 2026 Update	63
Association of MPL K39N and R102P heterozygous germline mutations lead to hereditary thrombocytosis	63
Aspirin use in essential thrombocythemia: Once‐daily or twice‐daily or not at all?	59
Are veterans at increased risk of myeloproliferative neoplasms?	58
Primary Effusion Lymphoma Prognostic Score (PEL‐PS): A Validated International Prognostic Score in HIV‐Associated Primary Effusion Lymphoma	57
Overall Survival in Male Patients With Advanced Hematological Disease (Mostly Acute Leukemia) Is Influenced by CYP1B1 C432G Polymorphism and Donor Sex in Allogeneic Stem Cell Transpl	57
R‐miniCHOP versus R‐CHOP in elderly patients with diffuse large B‐cell lymphoma: A propensity matched population‐based study	57
History of Thrombosis at High Altitude Associates With Increased Erythropoietin	54
Intravenous Iron Associated Hypophosphatemia: Much More Than a Laboratory Curiosity	54
Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers	53
Relative prognostic value of flow cytometric measurable residual disease before allogeneic hematopoietic cell transplantation for adults with MDS/AML or AML	52
A First‐In‐Human Phase 1 Study of a Novel BCMA×CD3 Bispecific T Cell Engager EMB‐06 in Relapsed or Refractory Multiple Myeloma	51
Basiliximab for steroid‐refractory acute graft‐versus‐host disease: A real‐world analysis	51
Hematopoietic Stem Cell Transplantation in Patients With Myelofibrosis and Splanchnic Vein Thrombosis: A Case Series	50
Molecular and clinicopathologic characterization of pediatric histiocytoses	50
Critical Blue‐Green Neutrophilic Inclusions in the Context of CD19 CAR‐T Toxicity	50
Hemolysis after high‐dose intravenous immunoglobulin: An under‐appreciated sequelae	50
Table of Contents	50
Acute myeloid leukemia with mutated TP53: Is this newly proposed entity oversimplifying a complex group of neoplasms?	49
Hydroxyurea in pregnancy: Reframing the conversation	49
Persistent Sweet syndrome post‐hematopoietic stem cell transplantation heralding molecular relapse of myelofibrosis	48
Harnessing the prognostic potential of PHF6 mutations in chronic myelomonocytic leukemia	47
Bleeding Patterns and Clinical Outcomes in Patients With Systemic AL Amyloidosis‐Related Acquired Factor X Deficiency	43
International Consensus Classification for myeloid neoplasms at‐a‐glance	43
Toward an improved understanding of hypomethylating agent and venetoclax therapies	43
Efficacy, safety, and survival findings after long‐term follow‐up of ZGJAK002: A phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once daily (	42
Quick consults in hematology: Staging and treating immunoglobulin light chain (AL) amyloidosis	41
Repeated infusions of escalating doses of expanded and activated autologous natural killer cells in minimal residual disease‐positive Ph+ acute lymphoblastic leukemia patients. A GIMEMA phase 1 trial	41
Influence of racial and ethnic identity on overall survival in patients with chronic lymphocytic leukemia	41
	39
A Transfusion Reaction due to Anti‐ER5 in a Hyposplenic β0 Thalassemia Major Patient	39
A randomized double‐blind pilot study to evaluate the efficacy, safety, and tolerability of intravenous iron versus oral iron for the treatment of restless legs syndrome in patients with iron deficien	39
Rare circulating lymphoblasts with striking eosinophilia: A rare case of B‐lymphoblastic leukemia with PAX5::ZCCHC7	39
Socioeconomic marginalization and health outcomes in newly diagnosed multiple myeloma: A population‐based cohort study	39
Parameters Associated With Renal Recovery and Survival in Myeloma Patients With Acute Renal Failure to Cast Nephropathy	38
Donor Age Matters for Haploidentical HCT Patients Even After Adjusting for HLA Factors: A Machine Learning Approach	38
Decreasing alloimmunization‐specific mortality in sickle cell disease in the United States: Cost‐effectiveness of a shared transfusion resource	38
Impact of Switching From Race‐Based to Race‐Neutral Spirometry Reference Equations in Children With Sickle Cell Anemia	38
Patients with telomere biology disorders show context specific somatic mosaic states with high frequency of U2AF1 variants	37
POEMS syndrome: Update on diagnosis, risk‐stratification, and management	37
Phase 2 study of epigenetic priming with decitabine followed by cytarabine for acute myeloid leukemia in older patients	36
Sodium‐glucose co‐transporter‐2 inhibitor use and JAK2 unmutated erythrocytosis in 100 consecutive cases	36
Hairy cell leukemia 2022: Update on diagnosis, risk‐stratification, and treatment	35
A genomic‐augmented multivariate prognostic model for the survival of natural‐killer/T‐cell lymphoma patients from an international cohort	35
Combining CD34+ stem cell selection with prophylactic pathogen and leukemia directed T‐cell immunotherapy to simultaneously reduce graft versus host disease, infection, and leukemia recurre	35
Clinical characteristics, prognostic indicators, and survival outcomes in intravascular lymphoma: Mayo Clinic experience (2003–2018)	35
Lymphocyte Kinetics and Outcomes of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma With Out of Specification Products	35
Severe muscle bleeds in children and young adults with hemophilia A on emicizumab prophylaxis: Real‐world retrospective multi‐institutional cohort	35
Triple A Plus (AAA+) Survival Prediction Model for Essential Thrombocythemia: Analysis Involving 7308 Patients	34

Avatrombopag in immune thrombocytopenia: A real‐world study of the Spanish ITP Group (GEPTI)	34
Impaired pro‐resolving mechanisms promote abnormal NETosis, fueling autoimmunity in sickle cell disease	34
Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy	33
Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring	32
Treosulfan compared with reduced‐intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Fi	32
Peak absolute lymphocyte count after CAR‐T infusion predicts clinical response in aggressive lymphoma	32
Mini‐consolidations or intermediate‐dose cytarabine for the post‐remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries	32
Myelodysplastic/myeloproliferative neoplasm with neutrophilia (atypical chronic myeloid leukemia—aCML)	31
New drugs in myelofibrosis: Critical assessment of additional value to monotherapy with JAK inhibitors	31
Neutrophilic eccrine hidradenitis in a pediatric patient with acute myeloid leukemia	31
Pearson syndrome	31
A case of peripheral T‐cell lymphoma, NOS, mimicking acute monocytic leukemia	31
Issue Information	31
Comparison of fludarabine‐based conditioning regimens in adult cord blood transplantation for myeloid malignancy: A retrospective, registry‐based study	31
Posttreatment positivity of BCR::ABL1 in acute lymphoblastic leukemia: Should we keep track?	31
Myelokathexis in an 18‐year‐old male patient with severe neutropenia and lymphopenia	30
Transient receptor potential channel vanilloid type 2 in red cells of cannabis consumer	30
Superior GVHD‐Free, Relapse‐Free Survival for Haploidentical Transplant With PTCy Than Matched Unrelated Donor for AML Patients Transplanted in Second Complete Remissi	29
Practical Guidance on Clinical Management of Belantamab Mafodotin‐Associated Ocular Events	29
Ex Vivo IL‐15‐Stimulated NK Cells as Adoptive Cell Therapy in Haploidentical Transplantation for Pediatric Leukemia	29
A CRISPR view of hematopoietic stem cells: Moving innovative bioengineering into the clinic	29
Six‐week low‐molecular‐weight heparin versus 12‐week warfarin for calf deep vein thrombosis: A randomized, prospective, open‐label study	29
Correction to “Benefit of Axicabtagene Ciloleucel Versus Chemoimmunotherapy in Older Patients and/or Patients With Poor ECOG Performance Status With Relapsed or Refractory Large B‐Cell Lymp	28
Elevated MCHC reveals a Southeast Asian Ovalocytosis	28
LLM Abstracts Supplement	28
The Diversity of Spiculated Erythrocytes	28
A Case of Hodgkin Lymphoma in a Gaucher Disease Patient: Distinguishing Gaucher and Pseudo‐Gaucher Cells	28
Clinical Use of Eltrombopag and Avatrombopag in Pediatric ITP in China: A Real‐World Multicenter Retrospective Cohort Study	28
TACI variants as underlying condition in autoimmune neutropenia: Description of four cases	28
Intra‐tumoral and peripheral blood TIGIT and PD‐1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma	28
Intravenous immunoglobulin as a rescue therapy for severe adult autoimmune hemolytic anemia: Results from a French multicenter observational study	27
Hemolytic anemia and macrothrombocytopenia: A lipid problem?	27
Moderate–severe beta‐thalassemia intermedia phenotype caused by sextuplicated alpha‐globin gene allele in two beta‐thalassemia carriers	27
Immune thrombocytopenia newly diagnosed during pregnancy: Outcome for mothers and neonates and comparison with chronic immune thrombocytopenia during pregnancy	27
Insane in the membrane: A case of hereditary spherocytic pyropoikilocytosis	27
Different impacts of granulocyte colony‐stimulating factor administration on allogeneic hematopoietic cell transplant outcomes for adult acute myeloid leukemia according to graft type	27
Cost‐effectiveness of second‐line therapies in adults with chronic immune thrombocytopenia	26
Optimizing Asparaginase Treatment for Adolescent and Young Adult (AYA) Patients With Acute Lymphoblastic Leukemia: US Consensus Panel Recommendations	26
Innovation Alone Is Not Enough: The Urgent Need for Equitable Access in Thalassemia Care	26
First‐ versus second‐generation Bruton tyrosine kinase inhibitors in Waldenström's Macroglobulinemia: A systematic review and meta‐analysis	25
The prevalence and clinical outcomes of microangiopathic hemolytic anemia in patients with biopsy‐proven renal thrombotic microangiopathy	25
Clinical Factors Associated With Catheter‐Related VTE in Patients Undergoing Hematopoietic Cell Transplantation: A Multi‐Center Study	24
Targeting PIEZO1‐TMEM16F Coupling to Mitigate Sickle Cell Disease Complications	24
Hodgkin lymphoma: 2025 update on diagnosis, risk‐stratification, and management	24
Long‐term outcomes in light chain deposition disease‐analysis of a UK cohort	24
SARS‐CoV‐2 humoral responses following booster BNT162b2 vaccination in patients with B‐cell malignancies	24
Combination of Biological Aging and Genetic Susceptibility Helps Identifying At‐Risk Population of Venous Thromboembolism: A Prospective Cohort Study of 394 041 Participants	23
Long‐term pharmacodynamic and clinical effects of twice‐ versus once‐daily low‐dose aspirin in essential thrombocythemia: The ARES trial	23
Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor‐experienced patients with paroxysmal nocturnal hemoglobinuria	23
Tissue factor activity is increased in neutrophils from JAK2 V617F‐mutated essential thrombocythemia and polycythemia vera patients	23
Thirteen‐month‐old girl with hyporegenerative macrocytic anemia due to Brown–Vialetto–Van Laere syndrome 2	23
Associations of minor histocompatibility antigens with outcomes following allogeneic hematopoietic cell transplantation	23
Real‐world efficacy and safety of luspatercept and predictive factors of response in patients with transfusion‐dependent β‐thalassemia	23
A multicenter, retrospective study of accelerated venetoclax ramp‐up in patients with relapsed/refractory chronic lymphocytic leukemia	23
Myelodysplastic syndromes: 2023 update on diagnosis, risk‐stratification, and management	22
	22
Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow‐up of patients diagnosed 2002–2017 in a complete coverage and nationwide agnostic register study	22
Immunomodulatory cytokines and clonal dynamics in low‐risk myelodysplastic syndromes patients treated with luspatercept	22
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management	22
Therapeutic Advances and Future of Therapy in Acute Myeloid Leukemia	22
SARS‐CoV‐2 vaccination in patients with paroxysmal nocturnal hemoglobinuria: An Italian multicenter survey	22
Issue Information	22
Table of Contents	22
Unusual complications in the management of chronic lymphocytic leukemia	22
Quadruplets in newly diagnosed transplant‐ineligible multiple myeloma	21
Timing and outcomes of second‐line therapy in the era of daratumumab‐based frontline therapy in AL amyloidosis	21
Identification of a CAR‐Derived Clone by NGS‐Based MRD After Fully Human BCMA CAR T‐Cell Therapy in Multiple Myeloma	21
Peripheral CD5+ CD10+ B‐cell proliferation with atypical morphology attributable to human herpesvirus 6 infection following umbilical cord blood transplantation	21
Splenic Iron Overload Influence on Lumbar Spine BMD Reproducibility in β‐Thalassemia	21
Generating Off‐the‐Shelf Hematopoietic Stem Cells by “Stretching” Induced Pluripotent Stem Cells	21
Myopathy related to chronic Graft‐Versus‐Host Disease: From clinic to histological & immunological characterization by imaging mass cytometry	21
Evaluating ChatGPT as an educational resource for patients with multiple myeloma: A preliminary investigation	21
Reducing transfusion utilization for children with sickle cell anemia in sub‐Saharan Africa with hydroxyurea: Analysis from the phase I/II REACH trial	21
Correction to “Efficacy and Safety of Early‐Start Deferiprone in Infants and Young Children With Transfusion‐Dependent Beta Thalassemia: Evidence for Iron Shuttling to Transferrin in a Randomized, Dou	20
Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinemia: Patient outcomes and impact of bendamustine dosing	20
Real World Study on the Best CPX‐351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation	20
Hypomethylating Therapy With or Without Eltrombopag in Elderly Patients With Acute Myeloid Leukemia: Results From the Randomized, Placebo‐Controlled Phase 2 DELTA Trial	20
‘Phenoconversion’ in adult patients with β‐thalassemia	20
Combinatorial treatment options for highly resistant compound mutations in the kinase domain of the BCR::ABL1 fusion gene in Ph‐positive leukemias	20
TP53‐altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor‐based therapy: A retrospective analysis	20

The pleiotropic effects of α‐thalassemia on HbSS and HbSC sickle cell disease: Reduced erythrocyte cation co‐transport activity, serum erythropoietin, and transfusion burden, do	20
Autoimmunity in sickle cell disease: Analysis of a large cohort of adult patients	20
Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS‐CoV‐2 similar to natural infection regardless ongoing treatments: A study by	20
The MAGIC algorithm probability (MAP)‐guided preemptive therapy of acute graft versus host disease with methylprednisolone: A randomized controlled trial	19
Suppression of Hb Bart's to improve tissue oxygenation and fetal development in homozygous alpha‐thalassemia	19
Roxadustat versus placebo for patients with lower‐risk myelodysplastic syndrome: MATTERHORN phase 3, double‐blind, randomized controlled trial	19
Checkpoint inhibitor immunotherapy during pregnancy for relapsed–refractory Hodgkin lymphoma	19
SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms	19
Preliminary efficacy and safety of Relmacabtagene autoleucel (Carteyva) in adults with relapsed/refractory follicular lymphoma in China: A phase I/II clinical trial	19
SLN124, a GalNAc conjugated 19‐mer siRNA targeting tmprss6, reduces plasma iron and increases hepcidin levels of healthy volunteers	19
A 29‐gene signature associated with NOX2 discriminates acute myeloid leukemia prognosis and survival	18
High incidence of malaria in patients with sickle cell disease	18
Peripheral blood evidence of iron overload	18
Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition	18
Issue Information	18
Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T‐cell lymphoma in a Chinese population: A multicenter phase II trial	18
A predictive algorithm for identifying children with sickle cell anemia among children admitted to hospital with severe anemia in Africa	18
ALK‐positive histiocytosis of external auditory canal in a 3‐year‐old boy	18
JAK inhibitor treatment‐resistant splenomegaly before transplantation in myelofibrosis: Splenectomy or radiotherapy?	18
Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant‐ineligible patients with newly diagnosed multiple	18
2025 update on clinical trials in immune thrombocytopenia	18
Single‐dose versus low‐dose rituximab in corticosteroid‐resistant or relapsed ITP: A multicenter, randomized, controlled study	18
RETRACTION: A predictive model of herpes zoster after allogeneic hematopoietic stem cell transplantation: VZV reactivation following antiviral prophylaxis discontinuation	18
Frequent bleeding symptoms associated with autoimmune acquired factor XIII/13 deficiency due to anti‐factor XIII A and B subunit antibodies	18
Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory non‐Hodgkin lymphomas: A phase IB/II study	18
Venous thromboembolism after COVID‐19 vaccination in patients with thrombophilia	18
Efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice‐weekly bortezomib and dexamethasone in previously treated mult	18
Table of Contents	18
Acute hemolytic anemia after hematopoietic stem cell transplantation: An unusual invader	18
Thrombosis risk prediction in lymphoma patients: A multi‐institutional, retrospective model development and validation study	17
Hyperparathyroidism and the Hematologist	17
Real‐world implementation of the David–Carroll buprenorphine protocol for pain management in sickle cell disease	17
Frontline combination of ponatinib and hyper‐CVAD in Philadelphia chromosome‐positive acute lymphoblastic leukemia: 80‐months follow‐up results	17
Treatment discontinuation in chronic myeloid leukemia: When, how, and why?	17
Management of post‐autologous transplant relapse in patients with T‐cell lymphomas	17
Azathioprine/hydroxyurea preconditioning prior to nonmyeloablative matched sibling donor hematopoietic stem cell transplantation in adults with sickle cell disease: A prospective observational cohort	17
Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide‐exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA	17
Chronic neutrophilic leukemia: 2022 update on diagnosis, genomic landscape, prognosis, and management	17
Registry data analysis of hematopoietic stem cell transplantation on systemic chronic active Epstein–Barr virus infection patients in Japan	17
Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B‐cell lymphoma after 2 or	17
	17
Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myelo	17
Optimization of idarubicin and cytarabine induction regimen with homoharringtonine for newly diagnosed acute myeloid leukemia patients based on the peripheral blast clearance rate: A single‐arm, phase	17
Drug (vaccine)‐induced thrombocytopenia 2021: Diversity of pathogenesis and clinical features	17
Complement biology for hematologists	17
Expression of p53 protein isoforms predicts survival in patients with multiple myeloma	17
Space anemia unexplained: Red blood cells seem to be space‐proof	17
From Science to Solidarity: A Two‐Decade Collaboration in Thalassemia	17
Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes	17
Nobel prize in physiology or medicine 2021, receptors for temperature and touch: Implications for hematology	16
Aspirin prophylaxis for hereditary and acquired thrombotic thrombocytopenic purpura?	16
	16
Cardiovascular disease in patients with chronic lymphocytic leukemia: A Swedish nationwide register study with matched comparators	16
Residual Cerebrovascular Morbidity Despite Treatment in Pediatric Sickle Cell Disease Highlights Opportunities for Earlier, Intensified Monitoring and Treatment	16
Correction to “Analysis of 60 Patients with Relapsed or Refractory T‐cell Acute Lymphoblastic Leukemia and T‐cell Lymphoblastic Lymphoma Treated with CD7‐targeted Chimeric Antigen R	16
	16
Crizanlizumab and sickle cell disease: When should medications have their approval status revoked?	16
Polycythemia vera: 2024 update on diagnosis, risk‐stratification, and management	16
A growing panoply of options for patients with paroxysmal nocturnal hemoglobinuria	16
Classic Hairy Cell Leukemia With MAP2K1 Mutation: Diagnosis and Targeted Therapy	16
Clinical and Prognostic Significance of Additional Chromosomal Abnormalities at Diagnosis of Chronic Myeloid Leukemia	16
Comparative clinical efficacy and safety of biosimilar ABP 959 and eculizumab reference product in patients with paroxysmal nocturnal hemoglobinuria	16
Hypercoagulability, endotheliopathy, and inflammation approximating 1 year after recovery: Assessing the long‐term outcomes in COVID‐19 patients	16
Thalassemia enters a new age … And more lies ahead	16
Increased risk of venous thromboembolism in patients with gastrointestinal disorders	16
	16
Crystal‐storing lymphocytosis	16
Rate of major bleeding with ibrutinib versus bendamustine‐rituximab in chronic lymphocytic leukemia: A population‐based cohort study	15
Fulminant intravascular hemolysis resulting from Clostridium perfringens infection	15
The prognostic value of blood cellular indices in pulmonary embolism	15
Inherited thrombophilia gene mutations and risk of venous thromboembolism in patients with cancer: A systematic review and meta‐analysis	15
Prevalence and Risk Factors for Venous Thromboembolism in People With Inherited Bleeding Disorders: An ATHNdataset Study	15
Molecular and clinical characterization of transient antithrombin deficiency: A new concept in congenital thrombophilia	15
Poor Engraftment After Posttransplant Cyclophosphamide Graft‐Versus‐Host Disease Prophylaxis in Patients With Myelofibrosis	15
Granularity in disease classification impacts survival prediction in advanced systemic mastocytosis: A single institution study of 329 informative cases	15
Venetoclax and azacitidine therapy in acute myeloid leukemia patients with severe renal impairment	15
PD‐L1 overexpression correlates with JAK2‐V617F mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms	15
HERVs characterize normal and leukemia stem cells and represent a source of shared epitopes for cancer immunotherapy	15
Changing hemostatic management in post‐partum hemorrhage	15
Artificial intelligence generated leukemia cell images	14
Transdifferentiation of B‐lymphoblastic leukemia to histiocytic sarcoma after immunotherapy	14
Issue Information	14
Multi‐organ dysfunction secondary to abrupt discontinuation of voxelotor in a patient with severe sickle cell disease	14
Clonal hematopoiesis in unexplained cytopenias	14
Issue Information	14
TRAF3 alterations are frequent in del‐3′IGH chronic lymphocytic leukemia patients and define a specific subgroup with adverse clinical features	14
Thrombopoietin mimetic‐induced bone marrow fibrosis	14
Evaluation of the clinical significance of global mRNA alternative splicing in patients with acute myeloid leukemia	14
Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia	14
Therapeutic Targeting of the Activin Receptor Signaling Pathway: Proof of Concept in Myeloid Neoplasms	14
Outcomes of patients with limited‐stage plasmablastic lymphoma: A multi‐institutional retrospective study	14
Iron Deficiency in Familial Mediterranean Fever: A Study on 211 Adult Patients From the JIR Cohort	14
Hematopoietic stem cell transplantation from haploidentical offspring donors using post‐transplant cyclophosphamide versus human leukocyte antigen‐matched siblings in older patients with myelodysplast	14
COVID‐19 mRNA vaccine‐associated cerebral venous thrombosis: Rare adverse event or coincidence?	14
A common pattern of somatic mutations in t‐MDS/AML of patients treated with PARP inhibitors for metastatic ovarian cancer	14